硝苯地平与阿托西班宫缩抑制对儿童结局的影响:APOSTEL III试验随访
APOSTEL III试验随访比较硝苯地平与阿托西班对2.5-5.5岁儿童结局的影响。196名母亲返回问卷(硝苯地平组115名儿童,阿托西班组110名儿童)。异常发育在硝苯地平组32名(30%),阿托西班组38名(38%),OR 0.74(95%CI 0.41-1.34)。神经发育、执行功能、行为及总体健康无显著差异。
要点
- 两药暴露儿童在神经发育、执行功能、行为及总体健康方面结局相当
- 异常发育复合结局两组无显著差异(OR 0.74,95%CI 0.41-1.34)
- 硝苯地平与阿托西班均不能被视为首选宫缩抑制治疗
核心结论
- 硝苯地平和阿托西班暴露儿童的广泛神经发育、执行功能、行为和总体健康结局相当。
- 两种药物均不能被视为有早产风险妇女的首选治疗。
研究设计与样本
- APOSTEL III试验为多中心随机对照试验,纳入503名有早产风险的妇女,比较硝苯地平与阿托西班宫缩抑制。
- 随访时请父母填写四份问卷,评估神经发育、执行功能、行为问题和总体健康。
主要发现
- 426名符合随访条件的妇女中,196名(46%)返回问卷,涵盖硝苯地平组115名儿童和阿托西班组110名儿童。
- 异常发育发生在硝苯地平组32名儿童(30%)和阿托西班组38名儿童(38%),OR 0.74(95%CI 0.41-1.34)。
- 神经发育、执行功能、行为和总体健康的单独结局在两组间无显著差异。
- 对所有APOSTEL III试验儿童的敏感性分析(包括死亡儿童比较)显示硝苯地平组健康存活率更高(64% vs 54%),但总体死亡率无显著差异(5.4% vs 2.7%)。
- 无显著亚组效应。
临床怎么用
- 对于有早产风险的妇女,硝苯地平和阿托西班在儿童长期神经发育、执行功能、行为和总体健康方面结局相当,均不能视为首选治疗。
局限性
- 随访问卷返回率为46%,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the long-term effects of tocolysis with nifedipine or atosiban on child outcome at age 2.5-5.5 years. DESIGN: The APOSTEL III trial was a multicentre randomised controlled trial that compared tocolysis with nifedipine or atosiban in 503 women with threatened preterm birth. Neonatal outcomes did not differ between both treatment arms, except for a higher incidence of intubation in the atosiban group. METHODS: Parents were asked to complete four questionnaires regarding neurodevelopment, executive function, behaviour problems and general health. MAIN OUTCOME MEASURES: The main long-term outcome measure was a composite of abnormal development at the age of 2.5-5.5 years. RESULTS: Of the 426 women eligible for follow-up, 196 (46%) parents returned the questionnaires for 115 children in the nifedipine group and 110 children in the atosiban group. Abnormal development occurred in 32 children (30%) in the nifedipine group and in 38 children (38%) in the atosiban group (OR 0.74, 95% CI 0.41-1.34). The separate outcomes for neurodevelopment, executive function, behaviour, and general health showed no significant differences between the groups. Sensitivity analysis for all children of the APOSTEL III trial, including a comparison of deceased children, resulted in a higher rate of healthy survival in the nifedipine group (64 versus 54%), but there was no significant difference in the overall mortality rate (5.4 versus 2.7%). There were no significant subgroup effects. CONCLUSION: Outcomes on broad child neurodevelopment, executive function, behaviour and general health were comparable in both groups. Neither nifedipine nor atosiban can be considered as the preferred treatment for women with threatened preterm birth. TWEETABLE ABSTRACT: Nifedipine- and atosiban-exposed children had comparable long-term outcomes, including neurodevelopment, executive function and behaviour.
引用
- van Winden T, Klumper J, Kleinrouweler CE, et al. Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial. BJOG. 2020. PMID: 32124520. doi:10.1111/1471-0528.16186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。